Concarlo Therapeutics

Insights from the postMONARCH study reveal the role of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer with ESR1 and PIK3CA mutations. What are your thoughts on how these findings might impact treatment strategies? Share your thoughts below! #breastcance

Expanding the modalities and mechanisms of action for therapies targeting novel pathways enhances the potential for successfully addressing various diseases. This approach increases the chances of successfully harnessing the full potential of targeting a novel pathway in treating diseases. Biotheryx is approaching CDK inhibition via small molecule degraders while we are approaching it p27 inhibiting small molecules with potential for dual inhibition of CDK2-CyclinE and CDK4/6-CyclinD complexes. #research #development #PrecisionMedicine 

We look forward to seeing Natalia Zisman, our Director of CMC and Dr. Krishna Allamneni, our EVP and Chief Development Officer,  speaking at the Biotech Symposium next month. Be sure to check out the other excellent speakers.  #Biotech #Networking #Science

Congratulations to Verzenio® (abemaciclib) HCP for being the most prescribed CDK4/6i. It’s exciting to see progress in treatment. 🎉 Meanwhile, at Concarlo Therapeutics, we continue to develop novel therapeutics to provide additional options for those who need them and improve outcomes for drug-resistant patients.  #research #development #patients #drugresistance 

The advancement in #AI is reshaping the landscape of clinical diagnosis! #EarlyDetection enables timely interventions and a better patient outcome. “As we continue to harness the power of AI in medicine, we're not just improving healthcare - we're redefining what's possible in our fight against diseases like cancer.” 

Access to medicines is crucial for improving patients' lives, just as our work on novel targets such as p27. At Concarlo Therapeutics, we're dedicated to developing not only safe and effective treatments but also those that are accessible due to cost-effectiveness. #PatientCare #Research #Oncology

Great insights on CDK2! It’s a fascinating illustration of the pivotal role CDK2 in regulating cellular proliferation by facilitating the transition from G1 to S phase. Indeed, CDK2's association with Cyclins E and A is crucial for DNA synthesis and cell cycle progression, and its dysregulation is linked to various cancers. Adding to this, did you know that targeting p27Kip1 can also help address CDK2 dysregulation in drug-resistant tumors? Our approach at Concarlo Therapeutics involves the development of small molecule therapeutics that inhibit CDK2/4/6 by modulating p27Kip1. By focusing on dual inhibition, we aim to overcome resistance in CDK4/6 and/or CDK2 inhibitor-resistant tumors, providing a novel, durable, and promising strategy for cancer treatment. Exciting advancements lie ahead as we continue to refine these innovative therapies for drug-resistant tumors! #CancerResearch #IndustryInsights Check out this informative video:

Connect with Concarlo Therapeutics at Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development in Carlsbad, CA. Our Director of CMC, Natalia Zisman, and our EVP, and Chief Development Officer, Dr. Krishna Allamneni will be presenting and participating at the Biotech Symposium 2024. Catch Natalia's workshop on 📅 Sunday, September 8th 🕞 3:30-4:10PM Workshop Title: "Lipid Nanoparticles: Do they live up to their promise of targeting tumors?” Catch Krishna’s workshop on 📅 Tuesday, September 10th 🕐 8:30 AM – 8:45 PM Session: Women’s Health and Research Overview   Don’t miss this chance to expand your knowledge and network with industry professionals. See you there! #ConcarloTherapeutics #Biotech #WomensHealth #BiotechSymposium2024  

The early signs of cancer are there.. and tech is being developed to find them. The future is coming. #cancerresearchworks

We want to call your attention to a timely new series on AJMC® Peer Exchange® peer-to-peer panel discussions featuring authoritative insights, opinions, and perspectives on important issues facing today’s managed care professionals. Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads an expert panel discussion on the use of CDK4/6 inhibitors in high-risk early breast cancer. With insights from renowned experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO, this series covers crucial updates, best practices in managing toxicity profiles, and navigating financial challenges to optimize patient outcomes. Don't miss out on this opportunity to learn about: - Factors influencing decisions to prescribe CDK4/6 inhibitors - Analysis of the monarchE and NATALEE trial results - Sequencing considerations with CDK4/6 inhibitors - Differences in toxicity profiles between abemaciclib and ribociclib - The impact of different endocrine therapies on toxicities Watch the series here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare #CDK46Inhibitors #Oncology #PatientCare #MedicalUpdates